Research and Development: Comparing Key Metrics for Bio-Techne Corporation and Apellis Pharmaceuticals, Inc.

Biotech R&D: Apellis vs. Bio-Techne's Decade of Innovation

__timestampApellis Pharmaceuticals, Inc.Bio-Techne Corporation
Wednesday, January 1, 2014837952230945000
Thursday, January 1, 20151373031140853000
Friday, January 1, 20162297859945187000
Sunday, January 1, 20174030387853514000
Monday, January 1, 201810528557655329000
Tuesday, January 1, 201922096877062413000
Wednesday, January 1, 202029992100065192000
Friday, January 1, 202142086900070603000
Saturday, January 1, 202238723600087140000
Sunday, January 1, 202335438700092493000
Monday, January 1, 202496664000
Loading chart...

Data in motion

A Decade of Innovation: R&D Trends in Biotech

In the ever-evolving world of biotechnology, research and development (R&D) is the lifeblood of innovation. Over the past decade, Apellis Pharmaceuticals, Inc. and Bio-Techne Corporation have demonstrated contrasting R&D investment strategies. Apellis Pharmaceuticals has shown a remarkable growth trajectory, with R&D expenses increasing by over 4,000% from 2014 to 2023. This surge underscores their commitment to pioneering new treatments and therapies. In contrast, Bio-Techne Corporation has maintained a steady increase in R&D spending, with a 200% rise over the same period, reflecting a more consistent approach to innovation.

While Apellis's R&D expenses peaked in 2021, Bio-Techne's investment continued to grow, reaching its highest in 2023. This divergence highlights the varied strategies companies employ to stay competitive in the biotech sector. As we look to the future, these trends offer valuable insights into the dynamic landscape of biotech innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025